Halofuginone ameliorates LPS-induced immune disorder of acute lung injury via CD14/NF-κB pathway / 中国免疫学杂志

ABSTRACT

Objective:To evaluate the regulatory effectsand underlying mechanism of halofuginone (HF) on lipopolysaccharide (LPS)-induced immune disorder of acute lung injury (ALI) in rat. Methods: Rats were treated with LPS and HF. Subsequently,HE staining was performed for pulmonarypathological lesion,apoptosis bodies were calculated by TUNEL assay,the levels of inflammatory factors were confirmed by ELISA assay and the level of CD14 was measured by flow cytometry. Protein levels were determined by Western blot. Results: Treatment of HF dose-dependently alleviated LPS-induced pulmonary injury and inhibited the formation of apoptosis bodies significantly. Meanwhile,HF notably inhibited inflammation of ALI rats,as demonstrated by decreased IL-1β,IL-6 and IL-18. Furthermore,postconditioning with HF markedly decreased CD14+cells. Moreover,HF dose-dependently attenuated the promotive effects of LPS on CD14,TLR4 and NF-κB p65. Conclusion: HF regulates LPS-induced immune disorder of ALI in rat via CD14/NF-κB pathway.